Positive DAT-SCAN in SPG7: a case report mimicking possible MSA-C.
Case report
DAT-SCAN imaging
Multiple system atrophy
Nigrostriatal denervation
SPG7
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
25 Aug 2021
25 Aug 2021
Historique:
received:
06
12
2020
accepted:
04
08
2021
entrez:
26
8
2021
pubmed:
27
8
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Spastic Paraplegia type 7 (SPG7) is one of the most common autosomal recessive Hereditary Spastic Paraplegias (HSP); Spastic Paraplegias (SPGs) can present as hereditary ataxias. However, ataxia is frequently the symptom of presentation of many other hereditary/sporadic disorders, such as Multiple system atrophy type C (MSA-C), an α-synuclein sporadic neurodegenerative disorder, in which cerebellar ataxia is one of the main clinical features. Dopamine Transporter imaging (DAT-SCAN), associated with clinical features, can be a helpful tool in order to distinguish MSA-C from other causes of ataxia. We present the case of a 70-year-old man with gait difficulties over a period of 3 years and frequent backward/lateral falls. He also reported urinary urge incontinence, but no symptoms that are compatible with orthostatic hypotension. On neurological examination he showed ataxic gait, spasticity in the left lower limb and trunk and limb ataxia, especially on the left side. Mild hypokinesia was found in all 4 limbs, especially in the left foot. MRI revealed atrophy of the cerebellar hemispheres and vermis. DAT-SCAN imaging revealed bilateral nigro-striatal degeneration, which was compatible with a diagnosis of possible MSA-C. Considering the atypical disease course (the patient walked without any support after 3 years), we carried out a genetic investigation for Ataxia, and a mutation in SPG7 was found. DAT-SCAN imaging, evaluated together with the clinical findings, can be useful for differentiating MSA from other possible causes of adult-onset Ataxia. Indeed, patients with MSA-C generally show a decreased uptake of dopamine transporters in DAT-SCAN imaging. Ours is the first case reported in the literature of a patient with SPG7 mutation with nigrostriatal degeneration and a clinical presentation of a possible MSA-C. Performing genetic investigations in patients with an atypical disease course is important to avoid MSA-mimicries. Identifying the correct diagnosis is important not only for prognostic reasons, but also for possible future genetic therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Spastic Paraplegia type 7 (SPG7) is one of the most common autosomal recessive Hereditary Spastic Paraplegias (HSP); Spastic Paraplegias (SPGs) can present as hereditary ataxias. However, ataxia is frequently the symptom of presentation of many other hereditary/sporadic disorders, such as Multiple system atrophy type C (MSA-C), an α-synuclein sporadic neurodegenerative disorder, in which cerebellar ataxia is one of the main clinical features. Dopamine Transporter imaging (DAT-SCAN), associated with clinical features, can be a helpful tool in order to distinguish MSA-C from other causes of ataxia.
CASE-PRESENTATION
UNASSIGNED
We present the case of a 70-year-old man with gait difficulties over a period of 3 years and frequent backward/lateral falls. He also reported urinary urge incontinence, but no symptoms that are compatible with orthostatic hypotension. On neurological examination he showed ataxic gait, spasticity in the left lower limb and trunk and limb ataxia, especially on the left side. Mild hypokinesia was found in all 4 limbs, especially in the left foot. MRI revealed atrophy of the cerebellar hemispheres and vermis. DAT-SCAN imaging revealed bilateral nigro-striatal degeneration, which was compatible with a diagnosis of possible MSA-C. Considering the atypical disease course (the patient walked without any support after 3 years), we carried out a genetic investigation for Ataxia, and a mutation in SPG7 was found.
CONCLUSIONS
CONCLUSIONS
DAT-SCAN imaging, evaluated together with the clinical findings, can be useful for differentiating MSA from other possible causes of adult-onset Ataxia. Indeed, patients with MSA-C generally show a decreased uptake of dopamine transporters in DAT-SCAN imaging. Ours is the first case reported in the literature of a patient with SPG7 mutation with nigrostriatal degeneration and a clinical presentation of a possible MSA-C. Performing genetic investigations in patients with an atypical disease course is important to avoid MSA-mimicries. Identifying the correct diagnosis is important not only for prognostic reasons, but also for possible future genetic therapies.
Identifiants
pubmed: 34433436
doi: 10.1186/s12883-021-02345-y
pii: 10.1186/s12883-021-02345-y
pmc: PMC8386044
doi:
Substances chimiques
Dopamine Plasma Membrane Transport Proteins
0
Metalloendopeptidases
EC 3.4.24.-
SPG7 protein, human
EC 3.4.24.-
ATPases Associated with Diverse Cellular Activities
EC 3.6.4.-
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
328Informations de copyright
© 2021. The Author(s).
Références
Brain. 2015 Nov;138(Pt 11):3316-26
pubmed: 26362908
Brain. 2012 Oct;135(Pt 10):2994-3004
pubmed: 22964162
Lancet Neurol. 2013 Mar;12(3):264-74
pubmed: 23391524
Mov Disord. 2012 Jun;27(7):913-6
pubmed: 22729987
Int Rev Neurobiol. 2019;149:137-192
pubmed: 31779811
Neurology. 2014 Nov 4;83(19):1733-8
pubmed: 25298309
Int Rev Neurobiol. 2018;143:109-162
pubmed: 30473193
Lancet Neurol. 2015 Jul;14(7):710-9
pubmed: 26025783
Lancet. 1983 May 21;1(8334):1151-5
pubmed: 6133167
J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):65-71
pubmed: 9667563
Ann Neurol. 2016 Mar;79(3):366-78
pubmed: 26605748
Neuroradiology. 2002 Mar;44(3):204-9
pubmed: 11942373
Neurology. 2017 Sep 5;89(10):1043-1049
pubmed: 28794257
Eur J Hum Genet. 2016 Jul;24(7):1016-21
pubmed: 26626314
Cell. 1998 Jun 12;93(6):973-83
pubmed: 9635427
J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1528-31
pubmed: 7798985
Mov Disord Clin Pract. 2018 Dec 06;6(2):174-175
pubmed: 30838319
Crit Rev Biochem Mol Biol. 2007 May-Jun;42(3):221-42
pubmed: 17562452
Mov Disord. 2014 Mar;29(3):294-304
pubmed: 24615754
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
BMC Neurosci. 2010 Apr 28;11:55
pubmed: 20426821
Ann Neurol. 2020 Dec;88(6):1132-1143
pubmed: 32939785
Mov Disord. 2019 Jul;34(7):975-984
pubmed: 31034671
Nat Genet. 2006 May;38(5):518-20
pubmed: 16604072
J Magn Reson Imaging. 2012 Feb;35(2):239-56
pubmed: 22271273
Nat Genet. 2019 Apr;51(4):649-658
pubmed: 30926972
Nat Rev Neurol. 2017 Apr;13(4):232-243
pubmed: 28303913
N Engl J Med. 2015 Jan 15;372(3):249-63
pubmed: 25587949
Continuum (Minneap Minn). 2019 Aug;25(4):1036-1054
pubmed: 31356292
Mov Disord. 2021 Jul;36(7):1644-1653
pubmed: 33576112
Neurol Sci. 2019 Jul;40(7):1335-1342
pubmed: 30927137
J Neurol. 2011 Dec;258(12):2248-53
pubmed: 21633903
Mov Disord. 2019 Oct;34(10):1547-1561
pubmed: 31433872